The new agreement continues to enable rapid & equitable access to Veklury for COVID-19 patients in EU & EEA Countries. The agreement has a 6mos. extension option & purchase the product over the next 1yr.
The conditional marketing authorization was based on the P-III trial to evaluate a 3-day course of Veklury in patients with COVID-19 which showed an 87% reduction in risk for the composite 1EPs of COVID-19-related hospitalization or all-cause death by 28 Day (0.7% vs 5.3%), no deaths were reported
The agreement follows the expiration of an original JPA signed in Oct 2020. Veklury was approved or authorized for temporary use in ~50 countries globally & has established a safety profile & minimal drug interactions in diverse populations
Ref: Gilead | Image: Gilead
